DB:0OX

Stock Analysis Report

Executive Summary

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Zymeworks's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0OX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.9%

0OX

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

130.6%

0OX

-13.5%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 0OX exceeded the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 0OX exceeded the German Market which returned -20.9% over the past year.


Shareholder returns

0OXIndustryMarket
7 Day10.9%-0.7%-0.6%
30 Day-8.9%-7.8%-16.6%
90 Day-27.5%-21.1%-26.0%
1 Year130.6%130.6%-13.3%-13.5%-18.6%-20.9%
3 Yearn/a14.1%12.9%-19.0%-25.8%
5 Yearn/a-9.6%-11.9%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is Zymeworks's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Zymeworks undervalued compared to its fair value and its price relative to the market?

5.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 0OX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 0OX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 0OX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0OX is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0OX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0OX is overvalued based on its PB Ratio (5.4x) compared to the DE Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Zymeworks forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-5.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0OX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0OX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0OX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0OX's revenue (35.5% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: 0OX's revenue (35.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 0OX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Zymeworks performed over the past 5 years?

-29.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0OX is currently unprofitable.

Growing Profit Margin: 0OX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0OX is unprofitable, and losses have increased over the past 5 years at a rate of -29.7% per year.

Accelerating Growth: Unable to compare 0OX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0OX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 0OX has a negative Return on Equity (-59.2%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zymeworks's financial position?


Financial Position Analysis

Short Term Liabilities: 0OX's short term assets ($311.8M) exceed its short term liabilities ($82.6M).

Long Term Liabilities: 0OX's short term assets ($311.8M) exceed its long term liabilities ($40.0M).


Debt to Equity History and Analysis

Debt Level: 0OX is debt free.

Reducing Debt: 0OX had no debt 5 years ago.


Balance Sheet

Inventory Level: 0OX has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0OX's debt is covered by short term assets (assets are 3.5108936795073E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0OX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 0OX has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 10.2% each year.


Next Steps

Dividend

What is Zymeworks's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0OX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0OX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0OX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0OX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0OX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Ali Tehrani (47yo)

no data

Tenure

US$3,278,069

Compensation

Dr. Ali Tehrani, Ph.D. is a Co-Founder of Zymeworks, Inc. and serves as its Chief Executive Officer and President. Dr. Tehrani has been an integral part of many of Zymeworks' corporate achievements, includ ...


CEO Compensation Analysis

Compensation vs Market: Ali's total compensation ($USD3.28M) is above average for companies of similar size in the German market ($USD1.93M).

Compensation vs Earnings: Ali's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ali Tehrani
Co-Founderno dataUS$3.28m0.69% $9.8m
Anthony Polverino
Chief Scientific Officer & Executive VP of Early Development1.58yrsUS$1.34m0.064% $904.8k
Kathryn O'Driscoll
Chief People Officer0.50yrUS$2.39mno data
Diana Hausman
Chief Medical Officer3.83yrsUS$1.40m0.012% $167.0k
Neil Klompas
Executive VP of Business Operations & CFOno dataUS$1.05m0.021% $297.5k
Surjit Dixit
Vice President of Technologyno dataUS$497.90kno data
John Babcook
Senior Vice President of Discovery Research4.08yrsUS$400.71kno data
Mark Hollywood
Senior Vice President of Technical & Manufacturing Operations1.08yrsno datano data
Daniel Dex
Corporate Secretaryno datano datano data
David Poon
Vice President of Business Development and Alliance Managementno datano datano data

1.6yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 0OX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ali Tehrani
Co-Founderno dataUS$3.28m0.69% $9.8m
Hollings Renton
Independent Director3.17yrsUS$172.16kno data
Lota Zoth
Independent Chair of the Board of Directors0.58yrUS$184.19kno data
Kenneth Hillan
Independent Director3.17yrsUS$107.79kno data
Kelvin Neu
Independent Director0.083yrno datano data
Susan Mahony
Independent Director0.83yrUS$392.85kno data
Natalie Sacks
Independent Director2.67yrsUS$160.61kno data
Troy Cox
Independent Director0.83yrUS$392.48k0.016% $234.0k

1.8yrs

Average Tenure

55yo

Average Age

Experienced Board: 0OX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 0OX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.7%.


Top Shareholders

Company Information

Zymeworks Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zymeworks Inc.
  • Ticker: 0OX
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.533b
  • Listing Market Cap: US$1.421b
  • Shares outstanding: 45.53m
  • Website: https://www.zymeworks.com

Number of Employees


Location

  • Zymeworks Inc.
  • 1385 West 8th Avenue
  • Suite 540
  • Vancouver
  • British Columbia
  • V6H 3V9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZYMENYSE (New York Stock Exchange)YesCommon SharesUSUSDApr 2017
ZYMETSX (The Toronto Stock Exchange)YesCommon SharesCACADApr 2017
0OXDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2017

Biography

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnership with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 23:59
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.